{
    "xml": "<topic id=\"PHP527\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/azathioprine\" basename=\"azathioprine\" title=\"AZATHIOPRINE\">\n<title>AZATHIOPRINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_519\" namespace=\"/interactions/list-of-drug-interactions/azathioprine\">Azathioprine</xref>\n</p>\n<data name=\"vtmid\">111165009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_699299946\" title=\"Antimetabolites\">Antimetabolites</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\r\n<data name=\"domainOfEffect\">  </data>\r\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP69133\" outputclass=\"drugAction\" rev=\"1.8\" parent=\"/drugs/azathioprine\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Azathioprine is metabolised to mercaptopurine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69047\" outputclass=\"indicationsAndDose\" rev=\"1.47\" parent=\"/drugs/azathioprine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe acute Crohn's disease</p>\n<p outputclass=\"therapeuticIndication\">Maintenance of remission of Crohn's disease</p>\n<p outputclass=\"therapeuticIndication\">Maintenance of remission of acute ulcerative colitis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>2&#8211;2.5&#8239;mg/kg daily, some patients may respond to lower doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Rheumatoid arthritis that has not responded to other disease-modifying drugs</p>\n<p outputclass=\"therapeuticIndication\">Severe systemic lupus erythematosus and other connective tissue disorders</p>\n<p outputclass=\"therapeuticIndication\">Polymyositis in cases of corticosteroid resistance</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially up to 2.5&#8239;mg/kg daily in divided doses, adjusted according to response, rarely more than 3&#8239;mg/kg daily; maintenance 1&#8211;3&#8239;mg/kg daily, consider withdrawal if no improvement within 3 months.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Autoimmune conditions</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;3&#8239;mg/kg daily, adjusted according to response, consider withdrawal if no improvement within 3 months, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or </i>by intravenous infusion.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Suppression of transplant rejection</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;2.5&#8239;mg/kg daily, adjusted according to response, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or</i> by intravenous infusion.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe refractory eczema, normal or high TPMT activity</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8211;3&#8239;mg/kg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe refractory eczema, intermediate TPMT activity</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>0.5&#8211;1.5&#8239;mg/kg daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Generalised myasthenia gravis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth or by intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 0.5&#8211;1&#8239;mg/kg daily, then increased to 2&#8211;2.5&#8239;mg/kg daily, dose is increased over 3&#8211;4 weeks, azathioprine is usually started at the same time as the corticosteroid and allows a lower maintenance dose of the corticosteroid to be used, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or </i>by intravenous infusion.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68950\" outputclass=\"unlicensedUse\" rev=\"1.28\" parent=\"/drugs/azathioprine\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Azathioprine doses given in BNF for suppression of transplant rejection and autoimmune conditions may differ from those in product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Use for severe refractory eczema is unlicensed.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69164\" outputclass=\"contraindications\" rev=\"1.13\" parent=\"/drugs/azathioprine\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<sectiondiv outputclass=\"additionalContraindications\">\n<sectiondiv outputclass=\"cautionsOrContraindicationsWithIndications\">\n<p outputclass=\"title\">When used for severe refractory eczema</p>\n<p>\n<ph outputclass=\"contraindication\">absent thiopurine methyltransferase (TPMT) activity</ph>; <ph outputclass=\"contraindication\">very low thiopurine methyltransferase (TPMT) activity</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69216\" outputclass=\"cautions\" rev=\"1.16\" parent=\"/drugs/azathioprine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Reduce dose in elderly</ph>; <ph outputclass=\"caution\">reduced thiopurine methyltransferase activity</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69031\" outputclass=\"interactions\" rev=\"1.15\" parent=\"/drugs/azathioprine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (azathioprine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68978\" outputclass=\"sideEffects\" rev=\"1.31\" parent=\"/drugs/azathioprine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hepatic veno-occlusive disease</ph>; <ph outputclass=\"sideEffect\">lymphoma</ph>; <ph outputclass=\"sideEffect\">pancreatitis</ph>; <ph outputclass=\"sideEffect\">pneumonitis</ph>; <ph outputclass=\"sideEffect\">red cell aplasia</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Arthralgia</ph>; <ph outputclass=\"sideEffect\">cholestatic jaundice</ph>; <ph outputclass=\"sideEffect\">colitis in patients also receiving corticosteroids</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">dose-related bone marrow suppression</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">hair loss</ph>; <ph outputclass=\"sideEffect\">herpes zoster infection</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">increased susceptibility to infections in patients also receiving corticosteroids</ph>; <ph outputclass=\"sideEffect\">interstitial nephritis</ph>; <ph outputclass=\"sideEffect\">liver impairment</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">neutropenia</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">rigors</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Red cell aplasia</p>\n<p>Cases of pure red cell aplasia have been reported with azathioprine; dose reduction or discontinuation should be considered under specialist supervision.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Neutropenia and thrombocytopenia</p>\n<p>Usually resolved by reducing the dose.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Nausea, vomiting and diarrhoea</p>\n<p>Nausea, vomiting and diarrhoea may occur, usually starting early during the course of treatment, and in rheumatoid arthritis is may be appropriate to withdraw the drug.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hypersensitivity reactions</p>\n<p>Hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) call for immediate withdrawal.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69261\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.17\" parent=\"/drugs/azathioprine\">\n<title>Allergy and cross-sensitivity</title>\n<body>\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\n<sectiondiv>\n<p>Contra-indicated in hypersensitivity to mercaptopurine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69018\" outputclass=\"pregnancy\" parent=\"/drugs/azathioprine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Transplant patients immunosuppressed with azathioprine should not discontinue it on becoming pregnant. However, there have been reports of premature birth and low birth-weight following exposure to azathioprine, particularly in combination with corticosteroids. Spontaneous abortion has been reported following maternal or paternal exposure.</p>\n<p>Azathioprine is teratogenic in <i>animal</i> studies.</p>\n<p>The use of azathioprine during pregnancy needs to be supervised in specialist units.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Treatment should not generally be initiated during pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69242\" outputclass=\"breastFeeding\" parent=\"/drugs/azathioprine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk in low concentration.</p>\n<p>No evidence of harm in small studies&#8212;use if potential benefit outweighs risk.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69095\" outputclass=\"hepaticImpairment\" parent=\"/drugs/azathioprine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInHepaticImpairment\">\n<sectiondiv>\n<p>Monitor liver function.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68992\" outputclass=\"renalImpairment\" parent=\"/drugs/azathioprine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Reduce dose.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68984\" outputclass=\"preTreatmentScreening\" rev=\"1.9\" parent=\"/drugs/azathioprine\">\n<title>Pre-treatment screening</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Thiopurine methyltransferase</p>\n<p>The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP68940\" outputclass=\"monitoringRequirements\" parent=\"/drugs/azathioprine\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor for toxicity throughout treatment.</p>\n<p>Monitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.</p>\n<p>Blood tests and monitoring for signs of myelosuppression are essential in long-term treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69278\" outputclass=\"directionsForAdministration\" rev=\"1.29\" parent=\"/drugs/azathioprine\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>For <i>intravenous injection</i>, give over at least 1 minute (followed by 50&#8239;mL sodium chloride intravenous infusion).</p>\n<p>For <i>intravenous infusion</i> (<i>Imuran</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% <i>or</i> Sodium Chloride 0.9%. Reconstitute 50&#8239;mg with 5&#8211;15&#8239;mL Water for Injections; dilute requisite dose to a volume of 20&#8211;200&#8239;mL with infusion fluid.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use</p>\n<p>Intravenous injection is alkaline and very irritant, intravenous route should therefore be used <b>only</b> if oral route not feasible.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69010\" outputclass=\"patientAndCarerAdvice\" rev=\"1.22\" parent=\"/drugs/azathioprine\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"title\">Bone marrow suppression</p>\n<p>Patients and their carers should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP527-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/azathioprine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension, oral solution, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75753\" title=\"Tablet\" namespace=\"/drugs/azathioprine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75824\" title=\"Powder for solution for injection\" namespace=\"/drugs/azathioprine/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78151\" namespace=\"/treatment-summaries/immune-response\" title=\"Immune response\" count=\"5\" rel=\"backlink\">Immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78316\" namespace=\"/treatment-summaries/inflammatory-bowel-disease\" title=\"Inflammatory bowel disease\" count=\"5\" rel=\"backlink\">Inflammatory bowel disease</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78375\" namespace=\"/treatment-summaries/eczema-and-psoriasis-drugs-affecting-the-immune-response\" title=\"Eczema and psoriasis, drugs affecting the immune response\" count=\"1\" rel=\"backlink\">Eczema and psoriasis, drugs affecting the immune response</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78421\" namespace=\"/treatment-summaries/rheumatic-disease-suppressing-drugs\" title=\"Rheumatic disease, suppressing drugs\" count=\"3\" rel=\"backlink\">Rheumatic disease, suppressing drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78505\" namespace=\"/treatment-summaries/neuromuscular-disorders\" title=\"Neuromuscular disorders\" count=\"2\" rel=\"backlink\">Neuromuscular disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78537\" namespace=\"/treatment-summaries/cytotoxic-drugs\" title=\"Cytotoxic drugs\" count=\"1\" rel=\"backlink\">Cytotoxic drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78556\" namespace=\"/treatment-summaries/platelet-disorders\" title=\"Platelet disorders\" count=\"1\" rel=\"backlink\">Platelet disorders</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78614\" namespace=\"/treatment-summaries/arthritis\" title=\"Arthritis\" count=\"2\" rel=\"backlink\">Arthritis</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_519\" namespace=\"/interactions/list-of-drug-interactions/azathioprine\" title=\"Azathioprine\" count=\"1\" rel=\"link\">Azathioprine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75753\" namespace=\"/drugs/azathioprine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75824\" namespace=\"/drugs/azathioprine/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP527",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/azathioprine",
    "basename": "azathioprine",
    "title": "AZATHIOPRINE",
    "interactants": [
        {
            "id": "bnf_int_519",
            "label": "Azathioprine"
        }
    ],
    "vtmid": "111165009",
    "drugClassification": [
        "Antimetabolites"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Azathioprine is metabolised to mercaptopurine.",
                "html": "<p>Azathioprine is metabolised to mercaptopurine.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Severe acute Crohn's disease",
                        "html": "Severe acute Crohn's disease"
                    },
                    {
                        "textContent": "Maintenance of remission of Crohn's disease",
                        "html": "Maintenance of remission of Crohn's disease"
                    },
                    {
                        "textContent": "Maintenance of remission of acute ulcerative colitis",
                        "html": "Maintenance of remission of acute ulcerative colitis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "2&#8211;2.5 mg/kg daily, some patients may respond to lower doses.",
                        "html": "<p>2&#8211;2.5&#8239;mg/kg daily, some patients may respond to lower doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Rheumatoid arthritis that has not responded to other disease-modifying drugs",
                        "html": "Rheumatoid arthritis that has not responded to other disease-modifying drugs"
                    },
                    {
                        "textContent": "Severe systemic lupus erythematosus and other connective tissue disorders",
                        "html": "Severe systemic lupus erythematosus and other connective tissue disorders"
                    },
                    {
                        "textContent": "Polymyositis in cases of corticosteroid resistance",
                        "html": "Polymyositis in cases of corticosteroid resistance"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially up to 2.5 mg/kg daily in divided doses, adjusted according to response, rarely more than 3 mg/kg daily; maintenance 1&#8211;3 mg/kg daily, consider withdrawal if no improvement within 3 months.",
                        "html": "<p>Initially up to 2.5&#8239;mg/kg daily in divided doses, adjusted according to response, rarely more than 3&#8239;mg/kg daily; maintenance 1&#8211;3&#8239;mg/kg daily, consider withdrawal if no improvement within 3 months.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Autoimmune conditions",
                        "html": "Autoimmune conditions"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous injection or by intravenous infusion",
                    "html": "By mouth or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;3 mg/kg daily, adjusted according to response, consider withdrawal if no improvement within 3 months, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion.",
                        "html": "<p>1&#8211;3&#8239;mg/kg daily, adjusted according to response, consider withdrawal if no improvement within 3 months, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or </i>by intravenous infusion.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Suppression of transplant rejection",
                        "html": "Suppression of transplant rejection"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous injection or by intravenous infusion",
                    "html": "By mouth or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;2.5 mg/kg daily, adjusted according to response, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion.",
                        "html": "<p>1&#8211;2.5&#8239;mg/kg daily, adjusted according to response, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or</i> by intravenous infusion.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe refractory eczema, normal or high TPMT activity",
                        "html": "Severe refractory eczema, normal or high TPMT activity"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "1&#8211;3 mg/kg daily.",
                        "html": "<p>1&#8211;3&#8239;mg/kg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe refractory eczema, intermediate TPMT activity",
                        "html": "Severe refractory eczema, intermediate TPMT activity"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "0.5&#8211;1.5 mg/kg daily.",
                        "html": "<p>0.5&#8211;1.5&#8239;mg/kg daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Generalised myasthenia gravis",
                        "html": "Generalised myasthenia gravis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth or intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By mouth or by intravenous injection or by intravenous infusion",
                    "html": "By mouth or by intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 0.5&#8211;1 mg/kg daily, then increased to 2&#8211;2.5 mg/kg daily, dose is increased over 3&#8211;4 weeks, azathioprine is usually started at the same time as the corticosteroid and allows a lower maintenance dose of the corticosteroid to be used, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) or by intravenous infusion.",
                        "html": "<p>Initially 0.5&#8211;1&#8239;mg/kg daily, then increased to 2&#8211;2.5&#8239;mg/kg daily, dose is increased over 3&#8211;4 weeks, azathioprine is usually started at the same time as the corticosteroid and allows a lower maintenance dose of the corticosteroid to be used, oral administration preferable, if not possible then can be given by intravenous injection (intravenous solution very irritant) <i>or </i>by intravenous infusion.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Azathioprine doses given in BNF for suppression of transplant rejection and autoimmune conditions may differ from those in product literature.",
                "html": "<p>Azathioprine doses given in BNF for suppression of transplant rejection and autoimmune conditions may differ from those in product literature.</p>"
            },
            {
                "type": "unlicensedUse",
                "textContent": "Use for severe refractory eczema is unlicensed.",
                "html": "<p>Use for severe refractory eczema is unlicensed.</p>"
            }
        ]
    },
    "contraindications": {
        "cautionsOrContraindicationsWithIndications": [
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "absent thiopurine methyltransferase (TPMT) activity",
                "html": "absent thiopurine methyltransferase (TPMT) activity",
                "specificity": {
                    "textContent": "When used for severe refractory eczema",
                    "html": "When used for severe refractory eczema",
                    "indications": [
                        "severe refractory eczema"
                    ]
                }
            },
            {
                "type": "cautionsOrContraindicationsWithIndications",
                "textContent": "very low thiopurine methyltransferase (TPMT) activity",
                "html": "very low thiopurine methyltransferase (TPMT) activity",
                "specificity": {
                    "textContent": "When used for severe refractory eczema",
                    "html": "When used for severe refractory eczema",
                    "indications": [
                        "severe refractory eczema"
                    ]
                }
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Reduce dose in elderly",
                "html": "Reduce dose in elderly"
            },
            {
                "type": "cautions",
                "textContent": "reduced thiopurine methyltransferase activity",
                "html": "reduced thiopurine methyltransferase activity"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (azathioprine).",
                "html": "<p>Appendix 1 (azathioprine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hepatic veno-occlusive disease",
                        "html": "Hepatic veno-occlusive disease",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "lymphoma",
                        "html": "lymphoma",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pancreatitis",
                        "html": "pancreatitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "pneumonitis",
                        "html": "pneumonitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "red cell aplasia",
                        "html": "red cell aplasia",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Arthralgia",
                        "html": "Arthralgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cholestatic jaundice",
                        "html": "cholestatic jaundice",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "colitis in patients also receiving corticosteroids",
                        "html": "colitis in patients also receiving corticosteroids",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dose-related bone marrow suppression",
                        "html": "dose-related bone marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hair loss",
                        "html": "hair loss",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "herpes zoster infection",
                        "html": "herpes zoster infection",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "increased susceptibility to infections in patients also receiving corticosteroids",
                        "html": "increased susceptibility to infections in patients also receiving corticosteroids",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "interstitial nephritis",
                        "html": "interstitial nephritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "liver impairment",
                        "html": "liver impairment",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "neutropenia",
                        "html": "neutropenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rigors",
                        "html": "rigors",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Red cell aplasia",
                "textContent": "Cases of pure red cell aplasia have been reported with azathioprine; dose reduction or discontinuation should be considered under specialist supervision.",
                "html": "<p>Cases of pure red cell aplasia have been reported with azathioprine; dose reduction or discontinuation should be considered under specialist supervision.</p>"
            },
            {
                "type": "advice",
                "title": "Neutropenia and thrombocytopenia",
                "textContent": "Usually resolved by reducing the dose.",
                "html": "<p>Usually resolved by reducing the dose.</p>"
            },
            {
                "type": "advice",
                "title": "Nausea, vomiting and diarrhoea",
                "textContent": "Nausea, vomiting and diarrhoea may occur, usually starting early during the course of treatment, and in rheumatoid arthritis is may be appropriate to withdraw the drug.",
                "html": "<p>Nausea, vomiting and diarrhoea may occur, usually starting early during the course of treatment, and in rheumatoid arthritis is may be appropriate to withdraw the drug.</p>"
            },
            {
                "type": "advice",
                "title": "Hypersensitivity reactions",
                "textContent": "Hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) call for immediate withdrawal.",
                "html": "<p>Hypersensitivity reactions (including malaise, dizziness, vomiting, diarrhoea, fever, rigors, myalgia, arthralgia, rash, hypotension and interstitial nephritis) call for immediate withdrawal.</p>"
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "textContent": "Contra-indicated in hypersensitivity to mercaptopurine.",
                "html": "<p>Contra-indicated in hypersensitivity to mercaptopurine.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Transplant patients immunosuppressed with azathioprine should not discontinue it on becoming pregnant. However, there have been reports of premature birth and low birth-weight following exposure to azathioprine, particularly in combination with corticosteroids. Spontaneous abortion has been reported following maternal or paternal exposure.\n\nAzathioprine is teratogenic in animal studies.\n\nThe use of azathioprine during pregnancy needs to be supervised in specialist units.",
                "html": "<p>Transplant patients immunosuppressed with azathioprine should not discontinue it on becoming pregnant. However, there have been reports of premature birth and low birth-weight following exposure to azathioprine, particularly in combination with corticosteroids. Spontaneous abortion has been reported following maternal or paternal exposure.</p><p>Azathioprine is teratogenic in <i>animal</i> studies.</p><p>The use of azathioprine during pregnancy needs to be supervised in specialist units.</p>"
            },
            {
                "type": "generalInformation",
                "textContent": "Treatment should not generally be initiated during pregnancy.",
                "html": "<p>Treatment should not generally be initiated during pregnancy.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk in low concentration.\n\nNo evidence of harm in small studies&#8212;use if potential benefit outweighs risk.",
                "html": "<p>Present in milk in low concentration.</p><p>No evidence of harm in small studies&#8212;use if potential benefit outweighs risk.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor liver function.",
                "html": "<p>Monitor liver function.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Reduce dose.",
                "html": "<p>Reduce dose.</p>"
            }
        ]
    },
    "preTreatmentScreening": {
        "preTreatmentScreening": [
            {
                "type": "preTreatmentScreening",
                "title": "Thiopurine methyltransferase",
                "textContent": "The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.",
                "html": "<p>The enzyme thiopurine methyltransferase (TPMT) metabolises thiopurine drugs (azathioprine, mercaptopurine, tioguanine); the risk of myelosuppression is increased in patients with reduced activity of the enzyme, particularly for the few individuals in whom TPMT activity is undetectable. Consider measuring TPMT activity before starting azathioprine, mercaptopurine, or tioguanine therapy. Patients with absent TPMT activity should not receive thiopurine drugs; those with reduced TPMT activity may be treated under specialist supervision.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor for toxicity throughout treatment.\n\nMonitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.\n\nBlood tests and monitoring for signs of myelosuppression are essential in long-term treatment.",
                "html": "<p>Monitor for toxicity throughout treatment.</p><p>Monitor full blood count weekly (more frequently with higher doses or if severe hepatic or renal impairment) for first 4 weeks (manufacturer advises weekly monitoring for 8 weeks but evidence of practical value unsatisfactory), thereafter reduce frequency of monitoring to at least every 3 months.</p><p>Blood tests and monitoring for signs of myelosuppression are essential in long-term treatment.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous injection, give over at least 1 minute (followed by 50 mL sodium chloride intravenous infusion).\n\nFor intravenous infusion (Imuran ), give intermittently in Glucose 5% or Sodium Chloride 0.9%. Reconstitute 50 mg with 5&#8211;15 mL Water for Injections; dilute requisite dose to a volume of 20&#8211;200 mL with infusion fluid.",
                "html": "<p>For <i>intravenous injection</i>, give over at least 1 minute (followed by 50&#8239;mL sodium chloride intravenous infusion).</p><p>For <i>intravenous infusion</i> (<i>Imuran</i>\n<tm tmtype=\"reg\"/>), give intermittently in Glucose 5% <i>or</i> Sodium Chloride 0.9%. Reconstitute 50&#8239;mg with 5&#8211;15&#8239;mL Water for Injections; dilute requisite dose to a volume of 20&#8211;200&#8239;mL with infusion fluid.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Intravenous injection is alkaline and very irritant, intravenous route should therefore be used only if oral route not feasible.",
                "html": "<p>Intravenous injection is alkaline and very irritant, intravenous route should therefore be used <b>only</b> if oral route not feasible.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Bone marrow suppression",
                "textContent": "Patients and their carers should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection.",
                "html": "<p>Patients and their carers should be warned to report immediately any signs or symptoms of bone marrow suppression e.g. inexplicable bruising or bleeding, infection.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension",
                "oral solution",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75753",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75824",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78151",
                "label": "Immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78316",
                "label": "Inflammatory bowel disease",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78375",
                "label": "Eczema and psoriasis, drugs affecting the immune response",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78421",
                "label": "Rheumatic disease, suppressing drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78505",
                "label": "Neuromuscular disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78537",
                "label": "Cytotoxic drugs",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78556",
                "label": "Platelet disorders",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78614",
                "label": "Arthritis",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_519",
                "label": "Azathioprine",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75753",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75824",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}